Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8, Novartis Extend Evaluation Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 Technology said Monday that it has extended a technology evaluation agreement with Novartis through Sept. 30, 2011.

Novartis will install Accelr8's BACcel system at its facility to "expand development capacity," Accelr8 said in a statement. It added that the firms will continue to negotiate and intend to agree on business terms for a formal collaboration by Sept. 30. The new agreement also includes an option for Novartis to extend project support through Jan. 2, 2012.

Novartis began evaluating the BACcel system, a rapid bacterial diagnostics system, in June 2010. Though it didn't name Novartis as the partner at that time, Accelr8 subsequently disclosed that the partner was Novartis in a filing with the US Securities and Exchange Commission.

As the firms have extended the evaluation pact over the past year Accelr8's shares have continued to rise. For the first half of 2011, the Denver-based firm's stock rose more than 300 percent.

In early Monday trade on the American Stock Exchange, shares of Accelr8 were up 12 percent at $4.15.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.